Novo Nordisk
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.About NVO
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.
NVO Key Statistics
Stock Snapshot
Novo Nordisk(NVO) stock is priced at $46.36, giving the company a market capitalization of 206.03B. It carries a P/E multiple of 13.60 and pays a dividend yield of 2.6%.
As of 2025-12-10, Novo Nordisk(NVO) stock has fluctuated between $46.08 and $47.03. The current price stands at $46.36, placing the stock +0.6% above today's low and -1.4% off the high.
Novo Nordisk(NVO) shares are trading with a volume of 10.25M, against a daily average of 15.77M.
In the last year, Novo Nordisk(NVO) shares hit a 52-week high of $112.52 and a 52-week low of $43.08.
In the last year, Novo Nordisk(NVO) shares hit a 52-week high of $112.52 and a 52-week low of $43.08.
NVO News
Mixed options sentiment in Novo Nordisk (NVO), with shares down 12c near $46.65. Options volume relatively light with 44k contracts traded and calls leading put...
Novo Nordisk (NVO) shares have slipped over the past week and remain well below their highs this year, even though revenue and net income are still growing at m...
Biotech Structure Therapeutics’ (GPCR) shares rallied 102.49% on Monday after mid-stage data for its obesity pill topped competing offerings from Eli Lilly (LLY...
Analyst ratings
55%
of 33 ratingsMore NVO News
It continues to be pounded by competition and challenges coming from numerous directions. Novo Nordisk (NVO 2.30%) stock was slimming down on Monday, but not i...
Biotech and Pharma Obesity Biotechs’ Gains Hit Shares of Eli Lilly, Novo Nordisk In this article NOVO.B LLY GPCR WVE SPX The market for GLP-1 weight-loss drugs...
JPMorgan analyst Richard Vosser lowered the firm’s price target on Novo Nordisk (NVO) to DKK 350 from DKK 500 and keeps an Overweight rating on the shares. Tip...
Argus downgraded Novo Nordisk (NVO) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try...
If you have been wondering whether Novo Nordisk is starting to look like a bargain after its big run in recent years, you are not alone. This breakdown is desig...
Key Points Novo Nordisk's semaglutide failed in pivotal studies as a treatment for Alzheimer's disease. This isn't a significant obstacle to the drugmaker's p...
Prices are going down for Novo Nordisk's weight-loss drug Wegovy. How much does Novo Nordisk’s weight-loss drug Wegovy actually cost? It depends on a patient’...
